West Oak Capital LLC Has $145,000 Position in Biogen Inc. (NASDAQ:BIIB)

West Oak Capital LLC lifted its position in shares of Biogen Inc. (NASDAQ:BIIB) by 2,000.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 945 shares of the biotechnology company’s stock after purchasing an additional 900 shares during the period. West Oak Capital LLC’s holdings in Biogen were worth $145,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Primecap Management Co. CA grew its position in shares of Biogen by 0.7% in the second quarter. Primecap Management Co. CA now owns 16,338,294 shares of the biotechnology company’s stock valued at $3,787,543,000 after purchasing an additional 117,578 shares during the last quarter. State Street Corp boosted its stake in Biogen by 3.5% in the 3rd quarter. State Street Corp now owns 7,344,960 shares of the biotechnology company’s stock valued at $1,423,747,000 after purchasing an additional 248,942 shares during the period. Geode Capital Management LLC grew its holdings in Biogen by 1.3% in the 3rd quarter. Geode Capital Management LLC now owns 3,613,020 shares of the biotechnology company’s stock valued at $698,062,000 after buying an additional 47,055 shares in the last quarter. RA Capital Management L.P. grew its holdings in Biogen by 20.6% in the 3rd quarter. RA Capital Management L.P. now owns 1,184,456 shares of the biotechnology company’s stock valued at $229,595,000 after buying an additional 202,317 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Biogen by 1.7% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,152,691 shares of the biotechnology company’s stock worth $223,438,000 after buying an additional 18,905 shares in the last quarter. Institutional investors own 87.93% of the company’s stock.

Biogen Trading Down 1.3 %

Shares of Biogen stock traded down $1.93 on Friday, hitting $148.82. 1,256,254 shares of the company’s stock traded hands, compared to its average volume of 1,168,559. The company has a market capitalization of $21.69 billion, a price-to-earnings ratio of 13.44, a price-to-earnings-growth ratio of 1.74 and a beta of -0.07. The company has a fifty day moving average of $157.88 and a two-hundred day moving average of $188.34. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.26 and a quick ratio of 0.80. Biogen Inc. has a one year low of $145.07 and a one year high of $252.94.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $4.08 EPS for the quarter, topping the consensus estimate of $3.77 by $0.31. Biogen had a net margin of 16.81% and a return on equity of 14.98%. The company had revenue of $2.47 billion during the quarter, compared to the consensus estimate of $2.43 billion. During the same quarter last year, the firm posted $4.36 EPS. The company’s quarterly revenue was down 2.5% on a year-over-year basis. As a group, sell-side analysts expect that Biogen Inc. will post 16.43 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms recently commented on BIIB. StockNews.com downgraded shares of Biogen from a “strong-buy” rating to a “buy” rating in a research note on Saturday, December 28th. Royal Bank of Canada lowered their target price on shares of Biogen from $292.00 to $269.00 and set an “outperform” rating on the stock in a report on Friday, October 4th. Wolfe Research began coverage on Biogen in a research note on Friday, November 15th. They issued a “peer perform” rating for the company. Robert W. Baird raised their price objective on Biogen from $294.00 to $300.00 and gave the stock an “outperform” rating in a research note on Friday, November 15th. Finally, Citigroup started coverage on Biogen in a research report on Thursday, November 14th. They set a “neutral” rating and a $190.00 target price for the company. Sixteen investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $230.00.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.